Clinical studies data on various mushrooms showing anticancer potential
| S. No. | Mushroom | Cancer | Phase | Bioactive components | Result |
|---|---|---|---|---|---|
| 1 | Agaricus bisporus | Breast cancer | Phase I completed | Polysaccharides, lectin | Reduced cancer by bringing down immunosuppressive factors. |
| Prostate cancer | Phase Ib completed, n = 32 | Polysaccharides, lectin | |||
| 2 | Agaricus blazei | Multiple myeloma | Phase II completed, randomized clinical trial, n = 100 | Genistein | Patients with cervical, ovarian, or endometrial cancer who were having chemotherapy did not vary significantly from those who were not treated with regard to lymphokine-activated killer or monocyte activity. Furthermore, verum only showed improvement in a number of negative effects when combined with mushroom extract. |
| 3 | Lentinula edodes | Prostate cancer | Phase II completed, n = 74 | CombinedPolysaccharide(GCP) | In individuals with early-stage prostate cancer, mushroom extract did not lower prostate specific antigen by more than 50%. |
| Hepatocellular carcinoma and hepatitis B & C | Phase II completed | Arabinoxylan | -- | ||
| 4 | Grifola frondosa | Breast and lung cancer | Phase I completed, n = 34 | Polysaccharides | In peripheral blood samples taken from postmenopausal breast cancer patients, maitake extracts had an effect on immunological stimulatory and inhibitory characteristics. |
| 5 | Omphalotus illudens | Thyroid cancer, metastatic or recurrent gastric cancer, recurrent or persistent epithelial ovarian cancer | Phase II completed | Illudin S semisynthetic derivative | -- |
| 6 | Trametes versicolor | Gastric cancer | Controlled trial, n = 60 | Krestin, PSK, PSP | Chemotherapy alleviated Qi and Yin deficit symptoms in gastric cancer patients. |
| 7 | Agaricus sylvaticus | Breast cancer | Randomized clinical trial, n = 46 | -- | Enhanced nutritional status with decreased side effects in stage II & III breast cancer patients, including nausea, vomiting, and anorexia. |
--: no description